Skip to main content
SpringerLink
Log in

Treatment of Autoimmune Hemolytic Anemia

  • Chapter
  • First Online:
Immune Hematology

Abstract

Autoimmune hemolytic anemia (AIHA) is a relatively uncommon disorder, characterized by autoreactive antibodies directed against endogenous red blood cell antigens. AIHA caused by warm-reacting antibodies is the most common form, and half of these are idiopathic. Excluding secondary causes of AIHA is the first step in treatment decision-making. Treatment of AIHA is also dictated by the type of causative antibody, patient’s age, and comorbidities. Warm AIHA responds well to corticosteroids initially, but a second-line, steroid-sparing treatment is commonly needed. Rituximab, splenectomy, and immunosuppressive medications are used as second-line treatment options in warm AIHA; however, the optimal order of these therapies is not yet known. Cold AIHA is usually part of an underlying illness or disease, and does not respond well to steroids or splenectomy; and rituximab is the first-line treatment in adult forms of monoclonal cold agglutinin disease. In this chapter, we discuss the treatment approaches to different forms of AIHA and emphasize differences between adult and pediatric AIHA. We also discuss novel treatment approaches, especially for specific forms of secondary AIHA, highlighting how unraveling the genetic mechanisms of AIHA can lead to more precise and effective therapies that avoid toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miano M. How I manage Evans syndrome and AIHA cases in children. Br J Haematol. 2016;172(4):524–34.

    Article  PubMed  Google Scholar 

  2. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. Haematologica. 2014;99(10):1547–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica. 2011;96(5):655–63.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, et al. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19):2930–6.

    Article  CAS  PubMed  Google Scholar 

  5. Segel GB, Lichtman MA. Direct antiglobulin (“Coombs”) test-negative autoimmune hemolytic anemia: a review. Blood Cells Mol Dis. 2014;52(4):152–60.

    Article  CAS  PubMed  Google Scholar 

  6. McGann PT, McDade J, Mortier NA, Combs MR, Ware RE. IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer. 2011;56(5):837–9.

    Article  PubMed  Google Scholar 

  7. Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. Blood. 2017;129(22):2971–9.

    Article  CAS  PubMed  Google Scholar 

  8. Lechner K, Jager U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831–8.

    Article  CAS  PubMed  Google Scholar 

  9. Garratty G. Drug-induced immune hemolytic anemia. Hematol Am Soc Hematol Educ Prog. 2009:73–9.

    Article  Google Scholar 

  10. Borthakur G, O’Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab—incidence and predictors. Br J Haematol. 2007;136(6):800–5.

    Article  CAS  PubMed  Google Scholar 

  11. Barcellini W. New insights in the pathogenesis of autoimmune hemolytic anemia. Transfus Med Hemother. 2015;42(5):287–93.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fattizzo B, Zaninoni A, Nesa F, Sciumbata VM, Zanella A, Cortelezzi A, et al. Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. Am J Hematol. 2015;90(8):E149–51.

    Article  PubMed  Google Scholar 

  13. Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion. 1999;39(1):6–10.

    Article  CAS  PubMed  Google Scholar 

  14. Petz LD. A physician’s guide to transfusion in autoimmune haemolytic anaemia. Br J Haematol. 2004;124(6):712–6.

    Article  PubMed  Google Scholar 

  15. Kalfa TA. Warm antibody autoimmune hemolytic anemia. Hematol Am Soc Hematol Educ Prog. 2016;2016(1):690–7.

    Google Scholar 

  16. Birgens H, Frederiksen H, Hasselbalch HC, Rasmussen IH, Nielsen OJ, Kjeldsen L, et al. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia. Br J Haematol. 2013;163(3):393–9.

    Article  CAS  PubMed  Google Scholar 

  17. Dussadee K, Taka O, Thedsawad A, Wanachiwanawin W. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. J Med Assoc Thail. 2010;93(Suppl 1):S165–70.

    Google Scholar 

  18. Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS, et al. Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies. Autoimmun Rev. 2015;14(4):304–13.

    Article  CAS  PubMed  Google Scholar 

  19. Dierickx D, Kentos A, Delannoy A. The role of rituximab in adults with warm antibody autoimmune hemolytic anemia. Blood. 2015;125(21):3223–9.

    Article  CAS  PubMed  Google Scholar 

  20. Maung SW, Leahy M, O’Leary HM, Khan I, Cahill MR, Gilligan O, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol. 2013;163(1):118–22.

    Article  CAS  PubMed  Google Scholar 

  21. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101(10):3857–61.

    Article  CAS  PubMed  Google Scholar 

  22. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119(16):3691–7.

    Article  CAS  PubMed  Google Scholar 

  23. Jaime-Perez JC, Rodriguez-Martinez M, Gomez-de-Leon A, Tarin-Arzaga L, Gomez-Almaguer D. Current approaches for the treatment of autoimmune hemolytic anemia. Arch Immunol Ther Exp. 2013;61(5):385–95.

    Article  CAS  Google Scholar 

  24. Akpek G, McAneny D, Weintraub L. Comparative response to splenectomy in coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999;61(2):98–102.

    Article  CAS  PubMed  Google Scholar 

  25. Centers for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. In: Hamborsky J, Kroger A, Wolfe S, editors, 13th ed. Washington, DC: Public Health Foundation; 2015.

    Google Scholar 

  26. Neven B, Bruneau J, Stolzenberg MC, Meyts I, Magerus-Chatinet A, Moens L, et al. Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. Blood. 2014;124(10):1597–609.

    Article  CAS  PubMed  Google Scholar 

  27. Rao VK, Dugan F, Dale JK, Davis J, Tretler J, Hurley JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol. 2005;129(4):534–8.

    Article  CAS  PubMed  Google Scholar 

  28. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117(3):712–5.

    Article  CAS  PubMed  Google Scholar 

  29. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60–4.

    Article  CAS  PubMed  Google Scholar 

  30. Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, et al. Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory primitive or secondary autoimmune cytopenias: a single centre experience. Br J Haematol. 2015.

    Google Scholar 

  31. Acquazzino MA, Fischer RT, Langnas A, Coulter DW. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor. Pediatr Transplant. 2013;17(5):466–71.

    Article  PubMed  Google Scholar 

  32. Valentini RP, Imam A, Warrier I, Ellis D, Ritchey AK, Ravindranath Y, et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant. 2006;10(3):358–61.

    Article  PubMed  Google Scholar 

  33. Miano M, Calvillo M, Palmisani E, Fioredda F, Micalizzi C, Svahn J, et al. Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children. Br J Haematol. 2014;167(4):571–4.

    Article  CAS  PubMed  Google Scholar 

  34. Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127(1):17–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol. 2009;145(1):101–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol. 1993;44(4):237–42.

    Article  CAS  PubMed  Google Scholar 

  37. Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anaemia. Br J Haematol. 1993;83(2):343–5.

    Article  CAS  PubMed  Google Scholar 

  38. Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100(2):704–6.

    Article  CAS  PubMed  Google Scholar 

  39. Passweg JR, Rabusin M. Hematopoetic stem cell transplantation for immune thrombocytopenia and other refractory autoimmune cytopenias. Autoimmunity. 2008;41(8):660–5.

    Article  CAS  PubMed  Google Scholar 

  40. Snowden JA, Saccardi R, Allez M, Ardizzone S, Arnold R, Cervera R, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770–90.

    Article  CAS  PubMed  Google Scholar 

  41. Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, et al. Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant. 2014;20(10):1654–9.

    Article  CAS  PubMed  Google Scholar 

  42. Nader K, Patel M, Ferber A. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2013;13(4):511–3.

    Article  PubMed  Google Scholar 

  43. Karageorgas T, Zomas A, Kazakou P, Katsimbri P, Mantzourani M, Boumpas D. Successful treatment of life-threatening autoimmune haemolytic anaemia with ofatumumab in a patient with systemic lupus erythematosus. Rheumatology (Oxford). 2016;55(11):2085–7.

    Article  Google Scholar 

  44. Ma K, Caplan S. Refractory IgG warm autoimmune hemolytic anemia treated with Eculizumab: a novel application of anticomplement therapy. Case Rep Hematol. 2016;2016:9181698.

    PubMed  PubMed Central  Google Scholar 

  45. Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951;87(1):48–65.

    Article  CAS  PubMed  Google Scholar 

  46. Teachey DT, Manno CS, Axsom KM, Andrews T, Choi JK, Greenbaum BH, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood. 2005;105(6):2443–8.

    Article  CAS  PubMed  Google Scholar 

  47. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132(2):125–37.

    Article  CAS  PubMed  Google Scholar 

  48. Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114(15):3167–72.

    Article  CAS  PubMed  Google Scholar 

  49. Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, Robert A, et al. Rituximab therapy for childhood Evans syndrome. Haematologica. 2007;92(12):1691–4.

    Article  CAS  PubMed  Google Scholar 

  50. Miano M, Ramenghi U, Russo G, Rubert L, Barone A, Tucci F, et al. Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology. Br J Haematol. 2016;175(3):490–5.

    Article  CAS  PubMed  Google Scholar 

  51. Jasinski S, Weinblatt ME, Glasser CL. Sirolimus as an effective agent in the treatment of immune thrombocytopenia (ITP) and Evans syndrome (ES): a single Institution’s experience. J Pediatr Hematol Oncol. 2017;39(6):420–4.

    Article  CAS  PubMed  Google Scholar 

  52. Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol. 1997;19(5):433–7.

    Article  CAS  PubMed  Google Scholar 

  53. Oliveira JB, Bleesing JJ, Dianzani U, Fleisher TA, Jaffe ES, Lenardo MJ, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010;116(14):e35–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Price S, Shaw PA, Seitz A, Joshi G, Davis J, Niemela JE, et al. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood. 2014;123(13):1989–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Rao VK, Oliveira JB. How I treat autoimmune lymphoproliferative syndrome. Blood. 2011;118(22):5741–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Rao VK, Price S, Perkins K, Aldridge P, Tretler J, Davis J, et al. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer. 2009;52(7):847–52.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Walter JE, Farmer JR, Foldvari Z, Torgerson TR, Cooper MA. Mechanism-based strategies for the management of autoimmunity and immune dysregulation in primary immunodeficiencies. J Allergy Clin Immunol Pract. 2016;4(6):1089–100.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Gathmann B, Mahlaoui N, Ceredih, Gérard L, Oksenhendler E, Warnatz K, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116–26.

    Article  PubMed  Google Scholar 

  59. Heeney MM, Zimmerman SA, Ware RE. Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr. 2003;143(5):662–5.

    Article  PubMed  Google Scholar 

  60. Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155(4):498–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Gamez-Diaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137(1):223–30.

    Article  CAS  PubMed  Google Scholar 

  62. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Lee S, Moon JS, Lee CR, Kim HE, Baek SM, Hwang S, et al. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016;137(1):327–30.

    Article  PubMed  Google Scholar 

  64. Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–40.

    Article  CAS  PubMed  Google Scholar 

  65. Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bader-Meunier B, Armengaud JB, Haddad E, Salomon R, Deschênes G, Koné-Paut I, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005;146(5):648–53.

    Article  CAS  PubMed  Google Scholar 

  67. Roumier M, Loustau V, Guillaud C, Languille L, Mahevas M, Khellaf M, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients. Am J Hematol. 2014;89(9):E150–5.

    Article  CAS  PubMed  Google Scholar 

  68. Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006;15(4):223–31.

    Article  CAS  PubMed  Google Scholar 

  69. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics. 2009;123(1):e159–63.

    Article  PubMed  Google Scholar 

  70. Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24(9):966–72.

    Article  CAS  PubMed  Google Scholar 

  71. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2003;12(8):633–5.

    Article  CAS  PubMed  Google Scholar 

  72. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus. 2005;14(10):856–8.

    Article  CAS  PubMed  Google Scholar 

  73. Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114–21.

    Article  CAS  PubMed  Google Scholar 

  74. Berentsen S, Ulvestad E, Langholm R, Beiske K, Hjorth-Hansen H, Ghanima W, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006;91(4):460–6.

    PubMed  Google Scholar 

  75. Berentsen S, Ulvestad E, Gjertsen BT, Hjorth-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925–8.

    Article  CAS  PubMed  Google Scholar 

  76. Berentsen S, Randen U, Vagan AM, Hjorth-Hansen H, Vik A, Dalgaard J, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010;116(17):3180–4.

    Article  CAS  PubMed  Google Scholar 

  77. Berentsen S, Randen U, Oksman M, Birgens H, Tvedt THA, Dalgaard J, et al. Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial. Blood. 2017;130(4):537–41.

    Article  CAS  PubMed  Google Scholar 

  78. Carson KR, Beckwith LG, Mehta J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood. 2010;115(4):915.

    Article  CAS  PubMed  Google Scholar 

  79. Roth A, Huttmann A, Rother RP, Duhrsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood. 2009;113(16):3885–6.

    Article  PubMed  Google Scholar 

  80. Wouters D, Stephan F, Strengers P, de Haas M, Brouwer C, Hagenbeeket A, et al. C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood. 2013;121(7):1242–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Omar Niss MD & Russell E. Ware MD, PhD

Authors
  1. Omar Niss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Russell E. Ware MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Russell E. Ware MD, PhD .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, USA

    Jenny M. Despotovic

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Niss, O., Ware, R.E. (2018). Treatment of Autoimmune Hemolytic Anemia. In: Despotovic, J. (eds) Immune Hematology. Springer, Cham. https://doi.org/10.1007/978-3-319-73269-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-73269-5_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-73268-8

  • Online ISBN: 978-3-319-73269-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation